

ZERO Biotech Company Limited

HONG KONG'S END-TO-END RADIO-BIOMEDICAL PLATFORM • RADIOPHARMA • DIAGNOSTICS • THERAPEUTICS

SHAPING THE FUTURE OF CANCER CARE THROUGH CUTTING-EDGE NUCLEAR MEDICINE

About ZERO Biotech

- ZERO Biotech Co., Ltd. is a Hong Kong-based radiopharmaceutical company dedicated to the research and development, manufacturing, and commercialization of nuclear medicine (NM) solutions. As a member of Hong Kong Science Park, we are a leading radiopharmaceutical company in Hong Kong, strategically located in the city's nationally recognized biotechnology hub. Leveraging Hong Kong's unique position as a gateway between mainland China and the global market, ZERO Biotech is well positioned to accelerate innovation and deliver cutting-edge NM products to patients worldwide.
- Our subsidiary, RIT Biotech, operates a central radio-pharmacy and has been supplying major hospitals across Hong Kong since 2017. Over the years, we have emerged as a leading nuclear medicine provider in Hong Kong, with a presence in every major hospital throughout the territory. As of today, RIT Biotech remains the only central radio-pharmacy for theranostic applications in Hong Kong, and will be upgraded to a PIC/s GMP Manufacturer in the near future.
- Beyond our established role in manufacturing and distribution, we are equally focused on driving innovative R&D programs designed to tackle unmet needs in cancer diagnosis and treatment. By developing next-generation nuclear medicine products, we aim to strengthen Hong Kong's position as a biotechnology hub and contribute meaningfully to the advancement of precision oncology both locally and globally.




Meeting with Prof. Dong Sun - Secretary for Innovation, Technology and Industry of HKSAR



Compounding facility in Hong Kong since 2015

- ZERO Biotech brings together a diverse team of professionals—including medical doctors, radiopharmaceutical specialists, scientists, engineers, clinical specialists, and entrepreneurs—most of whom have strong roots and longstanding connections in Hong Kong. We are entering a phase of accelerated growth, as outlined in the following sections.



MOU signing with New Frontier Group for jointly promoting radioligand therapy in Greater Bay Area

ZERO Biotech has established strong distribution network in Hong Kong and China

- **Strong hospital network:** A leading nuclear medicine provider in Hong Kong, with a footprint across all major hospitals in the territory.
- **Broadened GBA footprint:** Partnered with New Frontier Group to roll out radiotheranostic applications across the Greater Bay Area and Mainland China, helping accelerate cross-border medical tourism into Hong Kong.
- **Broad radiopharmaceutical portfolio:** Secured access to a broad range of nuclear medicine products from leading global pharmaceutical companies.

Leading the Charge: ZERO Biotech's Quest for Nuclear Medicine Advancement

- **Development of multi-cancer theranostic drug based on FAPI:** We proudly announced that we are collaborating with Shanghai Institute of Material Medical - Chinese Academy of Sciences (SIMM-CAS), to develop the theranostic application of a novel FAPI molecule, GPFAP-04. Fibroblast activation protein (FAP) is overexpressed by cancer-associated fibroblasts (CAF) of several tumor entities, whereas FAP inhibitors (FAPI) emerge as promising tracers and theranostic molecule to assess and treat many types of cancer. Based on the First in Human (FIH) study results, Ga68-GPFAP-04 showed superior results than F18-FDG in various types of cancer.



Technology Transfer with SIMM-CAS for GPFAP-04 molecule

The gastric lesion, perihepatic, peritoneal and mesenteric metastases demonstrated more obvious [^{68}Ga]-DOTA-GPFAP-04 uptake (B-D) than [^{18}F]-FDG uptake (F-H)

- We have identified qualified CDMO companies for pharmaceutical studies, radiolabeling and preclinical studies to achieve FDA & NMPA IND application for Ga68-GPFAP-04 & Lu177-GPFAP-04, and the current round of fundraising will be mainly focusing on this milestone.
- **Exploration of next generation Terbium-161(Tb161)-based theranostic application:** Tb161 is a novel medical isotope that with scientific evidence showing it may have higher therapeutic effect than Lutetium 177(Lu177) while also have a safer profile than Actinium 225(Ac225). Following on securing the exclusive distribution agreement of the only GMP grade supplier in the world TerThera b.v., ZERO Biotech is exploring to expand our drug development programmes with Tb161, targeting proven targets such as PSMA or novel targets. We have successfully administered the **first Tb161 PSMA injection** to a patient in Hong Kong in July 2026.

Executive Team

- We adopt a technology-first approach. ZERO Biotech's Advisory Board, consisting of world-renowned nuclear medicine experts, gives industry insight and practical advice to the executive management team.
- Key members of our executive team include Mr. Clement Tam (CEO), trained at Stanford with M.S in Engineering and Dr. CM Lok (CMO), Specialist in Nuclear Medicine, Past President of Hong Kong Society of Nuclear Medicine and Molecular Imaging (2012-2018).
- Prof. Zhen Cheng, Professor and the Director of the Molecular Imaging Center, State Key Laboratory of Drug Research, SIMM-CAS is serving as Chairman of ZERO/SIMM-CAS Joint Scientific Committee.



Mr. Clement Tam
Chief Executive Officer



Dr. CM Lok
Chief Medical Officer

Key Investment Highlights

- **Massive Market Size:** Global cancer medicine market is projected to reach over USD400B by 2028 and the potential multi-cancer radio-drug FAPI could capture this market.
- **Experienced and Dedicated Management Team:** Our team comprises seasoned professionals who possess extensive experience in nuclear medicine, spanning from research and development to commercialization.
- **Extensive Global Network:** We have established robust relationships with key stakeholders in the Nuclear Medicine industry, both upstream and downstream.
- **Proven Track Record:** Radiopharmaceuticals have gained widespread acceptance among medical professionals, resulting in strong sales since 2018 and we have been riding on the wave since supplying radiopharmaceuticals to major hospitals in 2017.
- **Multiple Exit strategies:** Favourable criteria for IPOs across international markets and active M&A secondary market present abundance exit alternatives.

We are currently seeking an equity investment to expedite our projects and present a compelling investment opportunity.

Contact: Clement Tam, Founder & CEO | Clement.tam@zerobiotech.com | ZERObiotech.com

This teaser has been prepared by ZERO Biotech Co Ltd ("ZERO" or the "Company") and is general background information about the Company's activities at the date of this teaser. The information in this teaser is provided in summary form only and does not purport to be complete. This teaser does not contain all the information that is or may be material to investors or potential investors and should not be considered as advice or a recommendation to investors or potential investors in respect of the holding, purchasing or selling of securities or other financial instruments and does not take into account any investor's particular objectives, financial situation or needs. This teaser has been made to you solely for information purposes. This teaser may be amended and supplemented as the Company sees fit, may not be relied upon for the purpose of entering into any transaction and should not be construed as, nor be relied on in connection with, any offer or invitation to purchase or subscribe for, underwrite or otherwise acquire, hold or dispose of any securities of the Company, and shall not be regarded as a recommendation in relation to any such transaction whatsoever. The contents of this teaser should not be considered to be legal, tax, investment or other advice, and any investor or prospective investor considering the purchase or disposal of any securities of the Company should consult with its own counsel and advisers as to all legal, tax, regulatory, financial and related matters concerning an investment in or a disposal of such securities and as to their suitability for such investor or prospective investor.

ZERO Biotech